GALERA THERAPEUTICS, INC. (GRTX): Price and Financial Metrics


GALERA THERAPEUTICS, INC. (GRTX): $2.45

0.01 (+0.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GRTX Stock Price Chart Interactive Chart >

Price chart for GRTX

GRTX Price/Volume Stats

Current price $2.45 52-week high $2.85
Prev. close $2.44 52-week low $1.12
Day low $2.40 Volume 210,904
Day high $2.64 Avg. volume 154,160
50-day MA $1.77 Dividend yield N/A
200-day MA $1.59 Market Cap 69.83M

GALERA THERAPEUTICS, INC. (GRTX) Company Bio


Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.


GRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

GRTX Latest Social Stream


Loading social stream, please wait...

View Full GRTX Social Stream

Latest GRTX News From Around the Web

Below are the latest news stories about GALERA THERAPEUTICS INC that investors may wish to consider to help them evaluate GRTX as an investment opportunity.

Malvern-based Galera shares rise on FDA filing for lead cancer therapy drug

Shares of Chester County biopharmaceutical company developing new cancer therapies opened up 9% Monday after filing its first new drug application with the Food and Drug Administration. Galera Therapeutics (NASDAQ: GRTX) of Malvern is seeking approval for avasopasem as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer. There are no FDA-approved treatment for severe oral mucositis.

Yahoo | December 12, 2022

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

NDA based on two positive randomized, double-blinded, placebo-controlled trials which enrolled a total of 678 patientsMALVERN, Pa., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administr

Yahoo | December 12, 2022

Galera to Present at Piper Sandler Annual Healthcare Conference

MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:10 a.m. E.T. A live webcast of the

Yahoo | November 22, 2022

Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting showed tumor outcomes and overall survival maintained compared to placebo One-year ROMAN follow-up data also showed cisplatin-related chronic kidney disease reduced by 50% in avasopasem patients compared to placebo Meta-analysis of both randomized placebo-controlled trials of avasopasem (ROMAN and GT-201) further u

Yahoo | November 9, 2022

One Galera Therapeutics, Inc. (NASDAQ:GRTX) insider upped their stake by 50% in the previous year

Viewing insider transactions for Galera Therapeutics, Inc.'s ( NASDAQ:GRTX ) over the last year, we see that insiders...

Yahoo | November 7, 2022

Read More 'GRTX' Stories Here

GRTX Price Returns

1-mo 64.43%
3-mo 67.81%
6-mo 102.48%
1-year -10.58%
3-year -83.49%
5-year N/A
YTD 64.43%
2022 -67.54%
2021 -55.13%
2020 -22.26%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6904 seconds.